[GnRH agonists and breast pathology].

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Context:

• Breast cancer management has been transformed by understanding hormone receptors and developing targeted therapies.
• Oestrogen receptor presence significantly enhances response to hormone treatment, with further improvement seen in progesterone-positive cases.
• Luteinizing hormone-releasing hormone (LH-RH) analogs offer a method for medical castration.

Purpose:

• To review the efficacy of hormone receptor targeted therapies and medical castration in breast cancer management.
• To evaluate the combined use of LH-RH analogs and tamoxifen in pre-menopausal women with metastatic breast cancer.
• To assess the role of these therapies in the adjuvant setting for reducing relapse risk.

Summary:

• Hormone receptor status, particularly oestrogen and progesterone receptors, is crucial for predicting response to endocrine therapy in breast cancer.
• The combination of LH-RH analogs (inducing medical castration) and tamoxifen has demonstrated survival benefits in pre-menopausal women with metastatic disease.
• Meta-analyses and recent studies confirm the efficacy of these treatments in the adjuvant setting, reducing relapse rates and improving survival without relapse.
• Medical castration with LH-RH agonists combined with tamoxifen presents a reversible, outpatient-friendly alternative to radical treatments like radiotherapy or ovariectomy, with emerging evidence of direct anti-tumor effects.

Impact:

• These therapeutic strategies have revolutionized breast cancer treatment, improving response rates from 30% to 50-70%.
• The combination therapy offers a significant survival advantage and reduced relapse risk, particularly in pre-menopausal women.
• It provides a less invasive, reversible treatment option compared to traditional radical therapies.
• Further research into the direct anti-tumor effects could expand therapeutic applications.